In a recent publication in Nature , Ising et al. reported the effect of the NLRP3 inflammasome on Aβ-induced tau pathology in Alzheimer’s disease (AD). The findings indicate that NLRP3 may be a novel target for the treatment of AD. 1
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: